TIDMAGY

RNS Number : 1591W

Allergy Therapeutics PLC

05 November 2014

5 November 2014

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

Grant of Options

Allergy Therapeutics plc (AIM: AGY) announces that, pursuant to the Allergy Therapeutics plc Long Term Share Incentive Plan ('LTIP'), on 5 November 2014 provisional shares of 0.1 pence each in the share capital of the Company were awarded to the following Board Directors: Mr Manuel Llobet (Chief Executive Officer) and Mr Ian Postlethwaite (Finance Director) at nil cost, as follows:

 
 Director             Number of provisional   Date of distribution   Total provisional 
                          shares awarded                              shares held under 
                                                                            LTIPs 
                                                   4 November 
 Manuel Llobet               845,000                  2014               3,315,000 
                     ----------------------  ---------------------  ------------------- 
                                                   4 November 
 Ian Postlethwaite           422,500                  2014               1,657,500 
                     ----------------------  ---------------------  -------------------

The issuance and distribution of ordinary shares of 0.1 pence each under the LTIP is conditional on the Company's performance over the course of three years. The new Long Term Incentive Plan was adopted by the Board on 20 March 2013.

-Ends-

For further information

 
 Allergy Therapeutics                      +44 (0) 1903 845 820 
 Manuel Llobet, Chief Executive Officer 
 Ian Postlethwaite, Finance Director 
 www.allergytherapeutics.com 
 
 Peel Hunt LLP                             +44 (0) 20 7418 8900 
 James Steel / Clare Terlouw 
 
 FTI Consulting                            +44 (0) 20 3727 1000 
 Simon Conway/ Mo Noonan / Victoria 
  Foster Mitchell

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business with revenue of GBP42million achieved mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBIBDBCXGBGSS

Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Allergy Therapeutics Charts.
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Allergy Therapeutics Charts.